Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497652 · ClinicalTrials.gov registry record · Phase 4
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
A Phase 4 study of Parkinson's Disease, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01497652: Completed Phase 4 study of Parkinson's Disease, sponsored by Georgetown University.
NCT01497652 is a Phase 4 study of Parkinson's Disease that has completed, run by Georgetown University. The registered enrollment target is 34 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01497652, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II \& III at the end of week 14.
Primary Outcome
Best value is 30 and Worst Value is 0. Scores for a series of subscales are not combined for a total overall score.
Conditions Studied
Interventions
- DRUG Rasagiline
- DRUG Rasagiline/Placebo
Study Locations (1)
District of Columbia
- Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
What the finished NCT01497652 record still lists
NCT01497652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Rasagiline is the first listed.
NCT01497652 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01497652 about?
NCT01497652 is a clinical study titled "A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy". The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg...
What is the current status of trial NCT01497652?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2012-01. Estimated completion is 2015-03.
What conditions does trial NCT01497652 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01497652?
The interventions under investigation include: Rasagiline (DRUG), Rasagiline/Placebo (DRUG).
Who is sponsoring clinical trial NCT01497652?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01497652 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01497652's enrollment target sits among peer trials
34 99th of 158 higher than 60 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia